CoChat

Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases

Balestri, Wendy, Sharma, Ruchi, da Silva, Victor A., Bobotis, Bianca C., Curle, Annabel J., Kothakota, Vandana, Kalantarnia, Farnoosh, Hangad, Maria V., Hoorfar, Mina, Jones, Joanne L., Tremblay, Marie-Ève, El-Jawhari, Jehan J., Willerth, Stephanie M., Reinwald, Yvonne · 2024 · Journal of Neuroinflammation
Cited by 56

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative disorders caused by the interaction of genetic, environmental, and familial factors. These diseases have distinct pathologies and symptoms that are linked to specific cell populations in the brain. Notably, the immune system has been implicated in both diseases, with a particular focus on the dysfunction of microglia, the brain’s resident immune cells, contributing to neuronal loss and exacerbating symptoms. Researchers use models of the neuroimmune system to gain a deeper understanding of the physiological and biological aspects of these neurodegenerative diseases and how they progress. Several in vitro and in vivo models, including 2D cultures and animal models, have been utilized. Recently, advancements have been made in optimizing these existing models and developing 3D models and organ-on-a-chip systems, holding tremendous promise in accurately mimicking the intricate intracellular environment. As a result, these models represent a crucial breakthrough in the transformation of current treatments for PD and AD by offering potential for conducting long-term disease-based modeling for therapeutic testing, reducing reliance on animal models, and significantly improving cell viability compared to conventional 2D models. The application of 3D and organ-on-a-chip models in neurodegenerative disease research marks a prosperous step forward, providing a more realistic representation of the complex interactions within the neuroimmune system. Ultimately, these refined models of the neuroimmune system aim to aid in the quest to combat and mitigate the impact of debilitating neuroimmune diseases on patients and their families.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-024-03024-8

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 171

  1. Vedam-Mai V. Harnessing the immune system for the treatment of Parkinson’s disease. Brain Res. 2021;1758: 147308. · DOI
  2. Zieneldien T, Kim J, Sawmiller D, Cao C. The immune system as a therapeutic target for Alzheimer’s disease. Life. 2022;12(9):1440. · DOI
  3. Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;10(4): a033118. · DOI · Paper page
  4. Cetin S, Knez D, Gobec S, Kos J, Pišlar A. Cell models for Alzheimer’s and Parkinson’s disease: at the interface of biology and drug discovery. Biomed Pharmacother. 2022;149: 112924. · DOI
  5. Kim TW, Koo SY, Studer L. Pluripotent stem cell therapies for Parkinson disease: present challenges and future opportunities. Front Cell Dev Biol. 2020;8:729. · DOI
  6. Slanzi A, Iannoto G, Rossi B, Zenaro E, Constantin G. In vitro models of neurodegenerative diseases. Front Cell Dev Biol. 2020;8:328. · DOI · Paper page
  7. King E, O’Brien J, Donaghy P, Williams-Gray CH, Lawson RA, Morris CM, et al. Inflammation in mild cognitive impairment due to Parkinson’s disease, Lewy body disease, and Alzheimer’s disease. Int J Geriatr Psychiatry. 2019;34(8):1244–50. · DOI
  8. Degerskär ANW, Englund EM. Cause of death in autopsy-confirmed dementia disorders. Eur J Neurol. 2020;27(12):2415–21. · DOI
  9. Mockett BG, Richter M, Abraham WC, Müller UC. Therapeutic potential of secreted amyloid precursor protein APPsα. Front Mol Neurosci. 2017;10. · DOI · Paper page
  10. Zaretsky DV, Zaretskaia M. Degradation products of amyloid protein: are they the culprits? Curr Alzheimer Res. 2020;17(10):869–80. · DOI
  11. Rischel EB, Gejl M, Brock B, Rungby J, Gjedde A. In Alzheimer’s disease, amyloid beta accumulation is a protective mechanism that ultimately fails. Alzheimer’s & Dementia. 2022;19(3):771–83. · DOI
  12. Sinsky J, Majerova P, Kovac A, Kotlyar M, Jurisica I, Hanes J. Physiological tau interactome in brain and its link to tauopathies. J Proteome Res. 2020;19(6):2429–42. · DOI · Paper page
  13. Trojanowski JQ, Shin RW, Schmidt ML, Lee VMY. Relationship between plaques, tangles, and dystrophic processes in Alzheimer’s disease. Neurobiol Aging. 1995;16(3):335–40. · DOI
  14. Ferguson AC, Tank R, Lyall LM, Ward J, Celis-Morales C, Strawbridge R, et al. Alzheimer’s disease susceptibility gene apolipoprotein E (APOE) and blood biomarkers in UK biobank (N = 395,769). Beason-Held L, editor. J Alzheimer’s Dis. 2020;1–11. · DOI · Paper page
  15. Sutherland K, Li T, Cao C. Alzheimer’s disease and the immune system. SOJ Neurol. 2015;2(1). · DOI
  16. Tan AH, Hor JW, Chong CW, Lim SY. Probiotics for Parkinson’s disease: current evidence and future directions. JGH Open. 2021;5(4):414–9. · DOI · Paper page
  17. Piao J, Zabierowski S, Dubose BN, Hill EJ, Navare M, Claros N, et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell. 2021;28(2):217–29. · DOI · Paper page
  18. Qiu B, Bessler N, Figler K, Buchholz MB, Rios AC, Malda J, et al. Bioprinting neural systems to model central nervous system diseases. Adv Funct Mater. 2020;30(44):1910250. · DOI
  19. Jasmin M, Ahn EH, Voutilainen MH, Fombonne J, Guix C, Viljakainen T, et al. Netrin‐1 and its receptor DCC modulate survival and death of dopamine neurons and Parkinson’s disease features. EMBO J. 2020;40(3). · DOI
  20. Fouke KE, Wegman ME, Weber SA, Brady EB, Román-Vendrell C, Morgan JR. Synuclein regulates synaptic vesicle clustering and docking at a vertebrate synapse. Front Cell Dev Biol. 2021;26:9.
  21. Yoo G, Shin YK, Lee NK. The role of α-synuclein in SNARE-mediated synaptic vesicle fusion. J Mol Biol. 2023;435(1):167775. · DOI
  22. Li Y, Zhu Z, Chen J, Zhang M, Yang Y, Huang P. Dilated perivascular space in the midbrain may reflect dopamine neuronal degeneration in Parkinson’s disease. Front Aging Neurosci. 2020;12. · DOI
  23. Oliveira FPM, Walker Z, Walker RWH, Attems J, Castanheira JC, Silva Â, et al. 123I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease: a new quantitative analysis of autopsy confirmed cases. J Neurol Neurosurg Psychiatry. 2021;92(6):662–7. · DOI
  24. Hatton C, Reeve A, Lax NZ, Blain A, Ng YS, El-Agnaf O, et al. Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies. Acta Neuropathol Commun. 2020;8(1). · DOI
  25. Kalia LV, Lang AE. Parkinson’s disease. The Lancet. 2015;386(9996):896–912. · DOI · Paper page
  26. Lin WC, Lee PL, Lu CH, Lin CP, Chou KH. Linking stage-specific plasma biomarkers to gray matter atrophy in Parkinson disease. Am J Neuroradiol. 2021;42(8):1444–51. · DOI
  27. Chen Z, Wu B, Li G, Zhou L, Zhang L, Liu J. Age and sex differentially shape brain networks in Parkinson’s disease. CNS Neurosci Ther. 2023;29:1907. · DOI
  28. Picard K, Bisht K, Poggini S, Garofalo S, Golia MT, Basilico B, et al. Microglial-glucocorticoid receptor depletion alters the response of hippocampal microglia and neurons in a chronic unpredictable mild stress paradigm in female mice. Brain Behav Immun. 2021;97:423–39. · DOI · Paper page
  29. Basilico B, Ferrucci L, Ratano P, Golia MT, Grimaldi A, Rosito M, et al. Microglia control glutamatergic synapses in the adult mouse hippocampus. Glia. 2022;70(1):173–95. · DOI · Paper page
  30. Devanney NA, Stewart AN, Gensel JC. Microglia and macrophage metabolism in CNS injury and disease: the role of immunometabolism in neurodegeneration and neurotrauma. Exp Neurol. 2020;329: 113310. · DOI · Paper page
  31. Rocamora-Reverte L, Melzer FL, Würzner R, Weinberger B. The complex role of regulatory T cells in immunity and aging. Front Immunol. 2021;11. · DOI · Paper page
  32. Gross AL, Walker KA, Moghekar AR, Pettigrew C, Soldan A, Albert MS, et al. Plasma markers of inflammation linked to clinical progression and decline during preclinical AD. Front Aging Neurosci. 2019;11. · DOI · Paper page
  33. Morgan AR, Touchard S, Leckey C, O’Hagan C, Nevado-Holgado AJ, et al. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimer’s & Dementia. 2019;15(6):776–87. · DOI · Paper page
  34. St-Pierre MK, VanderZwaag J, Loewen S, Tremblay MÈ. All roads lead to heterogeneity: the complex involvement of astrocytes and microglia in the pathogenesis of Alzheimer’s disease. Front Cell Neurosci. 2022;16. · DOI
  35. Bennett FC, Liddelow SA. Microglia metabolic breakdown drives Alzheimer’s pathology. Cell Metab. 2019;30(3):405–6. · DOI
  36. St-Pierre MK, Šimončičová E, Bögi E, Tremblay MÈ. Shedding light on the dark side of the microglia. ASN Neuro. 2020;12:1759091420925335. · DOI · Paper page
  37. Sanchez-Sanchez JL, Giudici KV, Guyonnet S, Delrieu J, Li Y, Bateman RJ, et al. Plasma MCP-1 and changes on cognitive function in community-dwelling older adults. Alzheimer’s Res Ther. 2022;14(1):5. · DOI
  38. Machhi J, Yeapuri P, Lu Y, Foster E, Chikhale R, Herskovitz J, et al. CD4+ effector T cells accelerate Alzheimer’s disease in mice. J Neuroinflammation. 2021;18(1):272. · DOI · Paper page
  39. Zhou J, Geng Y, Su T, Wang Q, Ren Y, Zhao J, et al. NMDA receptor-dependent prostaglandin-endoperoxide synthase 2 induction in neurons promotes glial proliferation during brain development and injury. Cell Rep. 2022;38(13):110557. · DOI
  40. Plescher M, Seifert G, Hansen JN, Bedner P, Steinhäuser C, Halle A. Plaque-dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer’s disease mouse model. Glia. 2018;66(7):1464–80. · DOI · Paper page
  41. Franco-Bocanegra DK, Gourari Y, McAuley C, Chatelet DS, Johnston DA, Nicoll JAR, et al. Microglial morphology in Alzheimer’s disease and after Aβ immunotherapy. Sci Rep. 2021;11(1):15955. · DOI · Paper page
  42. Lee WJ, Liao YC, Wang YF, Lin IF, Wang SJ, Fuh JL. Plasma MCP-1 and cognitive decline in patients with Alzheimer’s disease and mild cognitive impairment: a two-year follow-up study. Sci Rep. 2018;8(1):1280. · DOI · Paper page
  43. Dai L, Wang Q, Lv X, Gao F, Chen Z, Shen Y. Elevated β-secretase 1 expression mediates CD4+ T cell dysfunction via PGE2 signalling in Alzheimer’s disease. Brain Behav Immun. 2021;98:337–48. · DOI
  44. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007;130(7):1787–98. · DOI · Paper page
  45. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258–64. · DOI · Paper page
  46. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(11):2958–69. · DOI · Paper page
  47. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet. 2010;42(9):781–5. · DOI · Paper page
  48. Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, Payami H. Evidence for more than one Parkinson’s disease-associated variant within the HLA region. PLoS ONE. 2011;6(11): e27109. · DOI · Paper page
  49. Pierce S, Coetzee GA. Parkinson’s disease-associated genetic variation is linked to quantitative expression of inflammatory genes. PLoS ONE. 2017;12(4): e0175882. · DOI · Paper page
  50. Li M, Wan J, Xu Z, Tang B. The association between Parkinson’s disease and autoimmune diseases: a systematic review and meta-analysis. Front Immunol. 2023;14:1103053. · DOI
  51. Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657–73. · DOI · Paper page
  52. Awogbindin IO, Ishola IO, St-Pierre MK, Carrier M, Savage JC, Di Paolo T, et al. Remodeling microglia to a protective phenotype in Parkinson’s disease? Neurosci Lett. 2020;735: 135164. · DOI
  53. De Biase LM, Schuebel KE, Fusfeld ZH, Jair K, Hawes IA, Cimbro R, et al. Local cues establish and maintain region-specific phenotypes of basal ganglia microglia. Neuron. 2017;95(2):341–56. · DOI · Paper page
  54. Tang Y, Li T, Li J, Yang J, Liu H, Zhang XJ, et al. Jmjd3 is essential for the epigenetic modulation of microglia phenotypes in the immune pathogenesis of Parkinson’s disease. Cell Death Differ. 2014;21(3):369–80. · DOI · Paper page
  55. Kouli A, Camacho M, Allinson K, Williams-Gray CH. Neuroinflammation and protein pathology in Parkinson’s disease dementia. Acta Neuropathol Commun. 2020;8:1–19. · DOI · Paper page
  56. Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–74. · DOI · Paper page
  57. Pellegrini C, D’Antongiovanni V, Miraglia F, Rota L, Benvenuti L, Di Salvo C, et al. Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology. NPJ Parkinsons Dis. 2022;8(1):9. · DOI · Paper page
  58. Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, et al. Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Mov Disord. 2016;31(7):995–1003. · DOI · Paper page
  59. Yan Z, Yang W, Wei H, Dean MN, Standaert DG, Cutter GR, et al. Dysregulation of the adaptive immune system in patients with early-stage Parkinson disease. Neurol Neuroimmunol Neuroinflamm. 2021;8(5). · DOI
  60. Contaldi E, Magistrelli L, Comi C. T lymphocytes in Parkinson’s disease. J Parkinson’s Dis. 2022;12(s1):S65–74. · DOI
  61. Li R, Tropea TF, Baratta LR, Zuroff L, Diaz-Ortiz ME, Zhang B, et al. Abnormal B-cell and Tfh-cell profiles in patients with Parkinson disease: a cross-sectional study. Neurol Neuroimmunol Neuroinflamm. 2022;9(2). · DOI
  62. Wang P, Luo M, Zhou W, Jin X, Xu Z, Yan S, et al. Global characterization of peripheral B cells in Parkinson’s disease by single-cell RNA and BCR sequencing. Front Immunol. 2022;13: 814239. · DOI
  63. Khachaturian ZS. The ‘aducanumab story’: will the last chapter spell the end of the ‘amyloid hypothesis’ or mark a new beginning? J Prevent Alzheimer’s Dis. 2022;9(2):190–2.
  64. Baruch K, Kertser A, Matalon O, Forsht O, Braiman S, Shochat E, et al. IBC-Ab002, an anti-PD-L1 monoclonal antibody tailored for treating Alzheimer’s disease. Alzheimer’s & Dementia. 2020;16(S9): e042978. · doi:10.1002/alz.042978
  65. Kang BW, Kim F, Cho JY, Kim SY, Rhee J, Choung JJ. Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions. Alzheimer’s Res Ther. 2022;14(1):1–17. · DOI
  66. Kaeberlein M, Galvan V. Rapamycin and Alzheimer’s disease: time for a clinical trial? Sci Transl Med. 2019;11(476). · DOI · Paper page
  67. Nørgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Møller DV, et al. Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer’s & Dementia. 2022;8(1). · DOI · Paper page
  68. Hua X, Church K, Walker W, L’Hostis P, Viardot G, Danjou P, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer’s disease: randomized, placebo-controlled, double-blind, phase I clinical trial. J Alzheimer’s Dis. 2022;86(3):1399. · DOI
  69. Mehanna R, Lai EC. Deep brain stimulation in Parkinson’s disease. Transl Neurodegener. 2013;2(1):22. · DOI
  70. Mehanna R, Bajwa JA, Fernandez H, Wagle Shukla AA, others. Cognitive impact of deep brain stimulation on Parkinson’s disease patients. Parkinson’s Dis. 2017;2017. · DOI
  71. Stoker TB, Barker RA. Recent developments in the treatment of Parkinson’s disease. F1000Res. 2020;9:862. · DOI · Paper page
  72. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. · DOI · Paper page
  73. Larkin HD. Lecanemab gains FDA approval for early Alzheimer disease. JAMA. 2023;329(5):363–363.
  74. Tran TN, Vo TNN, Frei K, Truong DD. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm. 2018;125:1109–17. · DOI
  75. Turcano P, Mielke MM, Bower JH, Parisi JE, Cutsforth-Gregory JK, Ahlskog JE, et al. Levodopa-induced dyskinesia in Parkinson disease: a population-based cohort study. Neurology. 2018;91(24):e2238–43. · DOI
  76. Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905–18. · DOI · Paper page
  77. Khalifeh M, Read MI, Barreto GE, Sahebkar A. Trehalose against Alzheimer’s disease: insights into a potential therapy. BioEssays. 2020;42(8):1900195. · DOI
  78. Jin LW, Di LJ, Nguyen HM, Singh V, Singh L, Chavez M, et al. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer’s disease. Ann Clin Transl Neurol. 2019;6(4):723–38. · DOI · Paper page
  79. Wang YL, Zhang Y, Xu J. Sodium oligomannate combined with rivastigmine may improve cerebral blood flow and cognitive impairment following CAR-T cell therapy: a case report. Front Oncol. 2022;18:12.
  80. Potter H, Woodcock JH, Boyd TD, Coughlan CM, O’Shaughnessy JR, Borges MT, et al. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer’s disease. Alzheimer’s & Dementia. 2021;7(1): e12158.
  81. Ward M, Long H, Schwabe T, Rhinn H, Tassi I, Salazar SV, et al. A phase 1 study of AL002 in healthy volunteers. Alzheimer’s & Dementia. 2021;17(S9): e054669. · DOI
  82. Torres-Acosta N, O’Keefe JH, O’Keefe EL, Isaacson R, Small G. Therapeutic potential of TNF-α inhibition for Alzheimer’s disease prevention. J Alzheimer’s Dis. 2020;78(2):619. · DOI · Paper page
  83. MacPherson KP, Sompol P, Kannarkat GT, Chang J, Sniffen L, Wildner ME, et al. Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. Neurobiol Dis. 2017;1(102):81. · DOI · Paper page
  84. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43(4):329–39. · DOI · Paper page
  85. Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2(6):377–91. · DOI · Paper page
  86. Nickerson P, Jeffery J, Rush D. Long-term allograft surveillance: the role of protocol biopsies. Curr Opin Urol. 2001;11(2):133–7. · doi:10.1097/00042307-200103000-00002
  87. Candini O, Grisendi G, Foppiani EM, Brogli M, Aramini B, Masciale V, et al. A novel 3D in vitro platform for pre-clinical investigations in drug testing, gene therapy, and immuno-oncology. Sci Rep. 2019;9(1):1–12. · DOI · Paper page
  88. Jin Z, Li X, Zhang X, Desousa P, Xu T, Wu A. Engineering the fate and function of human T-Cells via 3D bioprinting. Biofabrication. 2021;13(3): 035016. · DOI
  89. Gray JI, Westerhof LM, MacLeod MKL. The roles of resident, central and effector memory CD4 T-cells in protective immunity following infection or vaccination. Immunology. 2018;154(4):574–81. · DOI
  90. Snow AL, Oliveira JB, Zheng L, Dale JK, Fleisher TA, Lenardo MJ. Critical role for BIM in T cell receptor restimulation-induced death. Biol Direct. 2008;3(1):1–17. · DOI
  91. Leach DG, Young S, Hartgerink JD. Advances in immunotherapy delivery from implantable and injectable biomaterials. Acta Biomater. 2019;1(88):15–31. · DOI · Paper page
  92. Lu W, Wei Y, Cao Y, Xiao X, Li Q, Lyu H, et al. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. Cancer Immunol Immunother. 2021;70(12):3501–11. · DOI
  93. Goodridge JP, Reiser JW, Bjordahl R, Mandal M, Chang C, Clarck R, et al. Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response. Cancer Res. 2020;80(16_Supplement):2216–2216. · doi:10.1158/1538-7445.am2020-2216
  94. Egrilmez MY, Karabay U, Aydemir S, Baykara B, Husemoglu RB. The cellular responses of human macrophages seeded on 3D printed thermoplastic polyurethane scaffold. J Med Innovat Technol. 2021;3(2):40–5. · doi:10.51934/jomit.1042774
  95. Xiao J, Gao Y. The manufacture of 3D printing of medical grade TPU. Prog Addit Manuf. 2017;2(3):117–23. · DOI
  96. Huang X, He C, Lin G, Lu L, Xing K, Hua X, et al. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun. 2020;524(4):1064–71. · DOI
  97. Aldrich A, Kuss MA, Duan B, Kielian T. 3D bioprinted scaffolds containing viable macrophages and antibiotics promote clearance of Staphylococcus aureus craniotomy-associated biofilm infection. ACS Appl Mater Interfaces. 2019;11(13):12298–307. · DOI · Paper page
  98. Lefebvre M, Jacqueline C, Amador G, Le Mabecque V, Miegeville A, Potel G, et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents. 2010;36(6):542–4. · DOI
  99. Woitschach F, Kloss M, Schlodder K, Borck A, Grabow N, Reisinger EC, et al. In vitro study of the interaction of innate immune cells with liquid silicone rubber coated with Zwitterionic methyl methacrylate and thermoplastic polyurethanes. Materials. 2021;14(20):5972. · DOI
  100. de Medeiros LM, De Bastiani MA, Rico EP, Schonhofen P, Pfaffenseller B, Wollenhaupt-Aguiar B, et al. Cholinergic differentiation of human neuroblastoma SH-SY5Y cell line and its potential use as an in vitro model for Alzheimer’s disease studies. Mol Neurobiol. 2019;56(11):7355–67. · DOI · Paper page
  101. Gan L, Cookson MR, Petrucelli L, La Spada AR. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci. 2018;21(10):1300–9. · DOI · Paper page
  102. Zhao J, Liu X, Xia W, Zhang Y, Wang C. Targeting amyloidogenic processing of APP in Alzheimer’s disease. Front Mol Neurosci. 2020;4:13.
  103. Korecka JA, van Kesteren RE, Blaas E, Spitzer SO, Kamstra JH, Smit AB, et al. Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS ONE. 2013;8(5): e63862. · DOI · Paper page
  104. Brown DG, Wobst HJ. Opportunities and challenges in phenotypic screening for neurodegenerative disease research. J Med Chem. 2019;63(5):1823–40. · DOI
  105. Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, et al. Differentiation of human ES and Parkinson’s disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci. 2010;45(3):258–66. · DOI · Paper page
  106. Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci. 2010;107(36):15921–6. · DOI · Paper page
  107. Ochalek A, Szczesna K, Petazzi P, Kobolak J, Dinnyes A. Generation of cholinergic and dopaminergic interneurons from human pluripotent stem cells as a relevant tool for in vitro modeling of neurological disorders and therapy. Stem Cells Int. 2016;2016. · DOI
  108. Agholme L, Lindström T, Kågedal K, Marcusson J, Hallbeck M. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimer’s Dis. 2010;20(4):1069–82. · DOI · Paper page
  109. Hossini AM, Megges M, Prigione A, Lichtner B, Toliat MR, Wruck W, et al. Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer’s disease donor as a model for investigating AD-associated gene regulatory networks. BMC Genomics. 2015;16:1–22. · DOI · Paper page
  110. Sharma NS, Karan A, Lee D, Yan Z, Xie J. Advances in modeling Alzheimer’s disease in vitro. Adv Nanobiomed Res. 2021;1(12):2100097. · DOI
  111. Hernández-Sapiéns MA, Reza-Zaldívar EE, Cevallos RR, Márquez-Aguirre AL, Gazarian K, Canales-Aguirre AA. A three-dimensional Alzheimer’s disease cell culture model using iPSC-derived neurons carrying A246E mutation in PSEN1. Front Cell Neurosci. 2020;14:151. · DOI
  112. Taylor-Whiteley TR, Le Maitre CL, Duce JA, Dalton CF, Smith DP. Recapitulating Parkinson’s disease pathology in a three-dimensional human neural cell culture model. Dis Model Mech. 2019;12(4):dmm038042. · DOI
  113. Moreno EL, Hachi S, Hemmer K, Trietsch SJ, Baumuratov AS, Hankemeier T, et al. Differentiation of neuroepithelial stem cells into functional dopaminergic neurons in 3D microfluidic cell culture. Lab Chip. 2015;15(11):2419–28. · DOI · Paper page
  114. Fiore NJ, Ganat YM, Devkota K, Batorsky R, Lei M, Lee K, et al. Bioengineered models of Parkinson’s disease using patient-derived dopaminergic neurons exhibit distinct biological profiles in a 3D microenvironment. Cell Mol Life Sci. 2022;79(2):1–20. · DOI
  115. Abdelrahman S, Alsanie WF, Khan ZN, Albalawi HI, Felimban RI, Moretti M, et al. A Parkinson’s disease model composed of 3D bioprinted dopaminergic neurons within a biomimetic peptide scaffold. Biofabrication. 2022;14(4): 044103. · DOI
  116. Saylam E, Akkaya Y, Ilhan E, Cesur S, Guler E, Sahin A, et al. Levodopa-loaded 3D-printed poly (Lactic) acid/chitosan neural tissue scaffold as a promising drug delivery system for the treatment of Parkinson’s disease. Appl Sci. 2021;11(22):10727. · DOI
  117. Cuní-López C, Quek H, Oikari LE, Stewart R, Nguyen TH, Sun Y, et al. 3D models of Alzheimer’s disease patient microglia recapitulate disease phenotype and show differential drug responses compared to 2D. bioRxiv. 2021;2021–3. · DOI
  118. Sabate-Soler S, Louise Nickels S, Saraiva C, Berger E, Dubonyte U, Barmpa K, et al. Microglia integration into human midbrain organoids leads to increased neuronal maturation and functionality. Wiley Online Library. 2022;70(7):1267–88.
  119. Markus B, Anna-Sophie S, Simon G, Dominik L, Alice K, Marvin R, et al. Incorporation of stem cell-derived astrocytes into neuronal organoids to allow neuro-glial interactions in toxicological studies. Altex. 2020;37(3):409–28.
  120. Xu R, Boreland AJ, Li X, Erickson C, Jin M, Atkins C, et al. Developing human pluripotent stem cell-based cerebral organoids with a controllable microglia ratio for modeling brain development and pathology. Stem Cell Reports. 2021;16(8):1923–37. · DOI · Paper page
  121. Song L, Yuan X, Jones Z, Vied C, Miao Y, Marzano M, et al. Functionalization of brain region-specific spheroids with isogenic microglia-like cells. Sci Rep. 2019;9(1). · DOI · Paper page
  122. Ilaria R, Marta T, Gianluigi F, Diego A, Carmen G. 3D brain tissue physiological model with co-cultured primary neurons and glial cells in hydrogels. J Tissue Eng. 2020;11:1–13.
  123. Chemmarappally JM, Pegram HCN, Abeywickrama N, Fornari E, Hargreaves AJ, De Girolamo LA, et al. A co-culture nanofibre scaffold model of neural cell degeneration in relevance to Parkinson’s disease. Sci Rep. 2020;10(1):1–14. · DOI
  124. Rueda-Gensini L, Serna JA, Rubio D, Camilo Orozco J, Bolaños NI, Cruz JC, et al. Three-dimensional neuroimmune co-culture system for modeling Parkinson’s disease microenvironments in vitro. Biofabrication. 2023;15:45001. · DOI
  125. Sundaramoorthy TH, Castanho I. The Neuroepigenetic landscape of vertebrate and invertebrate models of neurodegenerative diseases. Epigenet Insights. 2022;4:15.
  126. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/Cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86(6):973–83. · DOI · Paper page
  127. Tassetto M, Kunitomi M, Andino R. Circulating immune cells mediate a systemic RNAi-based adaptive antiviral response in drosophila. Cell. 2017;169(2):314-325.e13. · DOI · Paper page
  128. Dhankhar J, Agrawal N, Shrivastava A. An interplay between immune response and neurodegenerative disease progression: an assessment using Drosophila as a model. J Neuroimmunol. 2020;15(346): 577302. · DOI
  129. Nagai J, Yu X, Papouin T, Cheong E. Behaviorally consequential astrocytic regulation of neural circuits. Neuron. 2021;109(4):576–96. · DOI · Paper page
  130. Sarparast M, Hinman J, Pourmand E, Vonarx D, Ramirez L, Ma W, et al. Cytochrome P450 and epoxide hydrolase metabolites in Aβ and tau-induced neurodegeneration: insights from Caenorhabditis elegans. bioRxiv. 2023;2023.10.02.560527. · DOI
  131. Tan L, Schedl P, Song HJ, Garza D, Konsolaki M. The Toll–>NFkappaB signaling pathway mediates the neuropathological effects of the human Alzheimer’s Abeta42 polypeptide in Drosophila. PLoS ONE. 2008;3(12):e3966. · DOI · Paper page
  132. Zarini-Gakiye E, Sanadgol N, Parivar K, Vaezi G. Alpha-lipoic acid ameliorates tauopathy-induced oxidative stress, apoptosis, and behavioral deficits through the balance of DIAP1/DrICE ratio and redox homeostasis: age is a determinant factor. Metab Brain Dis. 2021;36(4):669–83. · DOI
  133. Cowan CM, Sealey MA, Mudher A. Suppression of tau-induced phenotypes by vitamin E demonstrates the dissociation of oxidative stress and phosphorylation in mechanisms of tau toxicity. J Neurochem. 2021;157(3):684–94. · DOI
  134. Lohr KM, Frost B, Scherzer C, Feany MB. Biotin rescues mitochondrial dysfunction and neurotoxicity in a tauopathy model. Proc Natl Acad Sci U S A. 2020;117(52):33608–18. · DOI
  135. Siddique YH, Rahul A, Ara G, Afzal M, Varshney H, Gaur K, et al. Beneficial effects of apigenin on the transgenic Drosophila model of Alzheimer’s disease. Chem Biol Interact. 2022;366:110120. · DOI
  136. Barati A, Masoudi R, Yousefi R, Monsefi M, Mirshafiey A. Tau and amyloid beta differentially affect the innate immune genes expression in Drosophila models of Alzheimer’s disease and β- D Mannuronic acid (M2000) modulates the dysregulation. Gene. 2022;15(808): 145972. · DOI
  137. Nayak N, Mishra M. Drosophila melanogaster as a model to understand the mechanisms of infection mediated neuroinflammation in neurodegenerative diseases. J Integr Neurosci. 2022;21(2):66. · DOI
  138. Olsen AL, Feany MB. Parkinson’s disease risk genes act in glia to control neuronal α-synuclein toxicity. Neurobiol Dis. 2021;1(159): 105482. · DOI
  139. Ranjan VD, Qiu L, Tan EK, Zeng L, Zhang Y. Modelling Alzheimer’s disease: insights from in vivo to in vitro three-dimensional culture platforms. J Tissue Eng Regen Med. 2018;12(9):1944–58. · DOI
  140. Doncheva NT, Palasca O, Yarani R, Litman T, Anthon C, Groenen MAM, et al. Human pathways in animal models: possibilities and limitations. Nucleic Acids Res. 2021;49(4):1859–71. · DOI
  141. Dietrich K, Bouter Y, Müller M, Bayer TA. Synaptic alterations in mouse models for Alzheimer disease—a special focus on N-truncated abeta 4–42. Molecules. 2018;23(4):718. · DOI
  142. Roda AR, Esquerda-Canals G, Martí-Clúa J, Villegas S. Cognitive impairment in the 3xTg-AD mouse model of Alzheimer’s disease is affected by Aβ-immunotherapy and cognitive stimulation. Pharmaceutics. 2020;12(10):944. · DOI
  143. Li S, Jin M, Liu L, Dang Y, Ostaszewski BL, Selkoe DJ. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease. Acta Neuropathol Commun. 2018;6(1):121. · DOI · Paper page
  144. Weintraub MK, Kranjac D, Eimerbrink MJ, Pearson SJ, Vinson BT, Patel J, et al. Peripheral administration of poly I: C leads to increased hippocampal amyloid-beta and cognitive deficits in a non-transgenic mouse. Behav Brain Res. 2014;266:183–7. · DOI
  145. Loewen SM, Chavesa AM, Murray CJ, Traetta ME, Burns SE, Pekarik KH, et al. The outcomes of maternal immune activation induced with the viral mimetic poly I:C on microglia in exposed rodent offspring. Dev Neurosci. 2023;45(4):191–209. · DOI
  146. Meeuwsen S, Bsibsi M, Persoon-Deen C, Ravid R, van Noort JM. Cultured human adult microglia from different donors display stable cytokine, chemokine and growth factor gene profiles but respond differently to a pro-inflammatory stimulus. NeuroImmunoModulation. 2005;12(4):235–45. · DOI
  147. Stojkovska I, Wagner BM, Morrison BE. Parkinson’s disease and enhanced inflammatory response. Exp Biol Med. 2015;240(11):1387–95. · DOI · Paper page
  148. Deng I, Corrigan F, Zhai G, Zhou XF, Bobrovskaya L. Lipopolysaccharide animal models of Parkinson’s disease: recent progress and relevance to clinical disease. Brain Behavior Immunity-Health. 2020;4: 100060. · DOI · Paper page
  149. Cameron T, Bennet T, Rowe EM, Anwer M, Wellington CL, Cheung KC. Review of design considerations for brain-on-a-chip models. Micromachines (Basel). 2021;12(4):441. · DOI
  150. Cameron TC, Randhawa A, Grist SM, Bennet T, Hua J, Alde LG, et al. PDMS organ-on-chip design and fabrication: strategies for improving fluidic integration and chip robustness of rapidly prototyped microfluidic in vitro models. Micromachines (Basel). 2022;13(10):1573. · DOI
  151. Campbell SB, Wu Q, Yazbeck J, Liu C, Okhovatian S, Radisic M. Beyond polydimethylsiloxane: alternative materials for fabrication of organ-on-a-chip devices and microphysiological systems. ACS Biomater Sci Eng. 2020;7(7):2880–99. · DOI · Paper page
  152. Wu Q, Liu J, Wang X, Feng L, Wu J, Zhu X, et al. Organ-on-a-chip: recent breakthroughs and future prospects. Biomed Eng Online. 2020;19:1–19. · DOI · Paper page
  153. Sima F, Sugioka K, Vázquez RM, Osellame R, Kelemen L, Ormos P. Three-dimensional femtosecond laser processing for lab-on-a-chip applications. Nanophotonics. 2018;7(3):613–34. · DOI · Paper page
  154. Paoli R, Di Giuseppe D, Badiola-Mateos M, Martinelli E, Lopez-Martinez MJ, Samitier J. Rapid manufacturing of multilayered microfluidic devices for organ on a chip applications. Sensors. 2021;21(4):1382. · DOI
  155. Ko J, Park D, Lee S, Gumuscu B, Jeon NL. Engineering organ-on-a-chip to accelerate translational research. Micromachines (Basel). 2022;13(8):1200. · DOI
  156. Puryear JR III, Yoon JK, Kim Y. Advanced fabrication techniques of microengineered physiological systems. Micromachines (Basel). 2020;11(8):730. · DOI
  157. Kim J, Yoon T, Kim P, Bekhbat M, Kang SM, Rho HS, et al. Manufactured tissue-to-tissue barrier chip for modeling the human blood–brain barrier and regulation of cellular trafficking. Lab Chip. 2023;23:2990–3001. · DOI
  158. Convery N, Samardzhieva I, Stormonth-Darling JM, Harrison S, Sullivan GJ, Gadegaard N. 3D printed tooling for injection molded microfluidics. Macromol Mater Eng. 2021;306(11):2100464. · DOI
  159. Kane KIW, Jarazo J, Moreno EL, Fleming RMT, Schwamborn JC. Passive controlled flow for Parkinson’s disease neuronal cell culture in 3D microfluidic devices. Organs-on-a-Chip. 2020;2: 100005. · DOI
  160. Zhou Y, Qiao H, Xu F, Zhao W, Wang J, Gu L, et al. Bioengineering of a human physiologically relevant microfluidic blood–cerebrospinal fluid barrier model. Lab Chip. 2023;23:3002–15. · DOI
  161. Brown JA, Codreanu SG, Shi M, Sherrod SD, Markov DA, Neely MD, et al. Metabolic consequences of inflammatory disruption of the blood-brain barrier in an organ-on-chip model of the human neurovascular unit. J Neuroinflammation. 2016;13(1):1–17. · DOI · Paper page
  162. Salmon I, Grebenyuk S, Fattah ARA, Rustandi G, Pilkington T, Verfaillie C, et al. Engineering neurovascular organoids with 3D printed microfluidic chips. Lab Chip. 2022;22(8):1615–29. · DOI · Paper page
  163. Kang YJ, Diep YN, Tran M, Tran VTA, Ambrin G, Ngo H, et al. Three-dimensional human neural culture on a chip recapitulating neuroinflammation and neurodegeneration. Nat Protocols. 2023;18(9):2838–67. · DOI
  164. Park J, Baik SH, Mook-Jung I, Irimia D, Cho H. Mimicry of central-peripheral immunity in Alzheimer’s disease and discovery of neurodegenerative roles in neutrophil. Front Immunol. 2019;10:480449. · DOI · Paper page
  165. Seo S, Choi CH, Yi KS, Kim SU, Lee K, Choi N, et al. An engineered neurovascular unit for modeling neuroinflammation. Biofabrication. 2021;13(3): 035039. · DOI
  166. Seo S, Jang M, Kim H, Sung JH, Choi N, Lee K, et al. Neuro-glia-vascular-on-a-chip system to assess aggravated neurodegeneration via brain endothelial cells upon exposure to diesel exhaust particles. Adv Funct Mater. 2023;33(12):2210123. · DOI
  167. Jorfi M, D’Avanzo C, Kim DY, Irimia D. Three-dimensional models of the human brain development and diseases. Adv Healthc Mater. 2018;7(1). · DOI
  168. Jorfi M, D’avanzo C, Tanzi RE, Kim DY, Irimia D. Human neurospheroid arrays for in vitro studies of Alzheimer’s disease. Sci Rep. 2018;8(1):2450. · DOI · Paper page
  169. Fernandes JTS, Chutna O, Chu V, Conde JP, Outeiro TF. A novel microfluidic cell co-culture platform for the study of the molecular mechanisms of Parkinson’s disease and other synucleinopathies. Front Neurosci. 2016;10:227609. · DOI
  170. de Rus JA, Alpaugh M, Denis HL, Tancredi JL, Boutin M, Decaestecker J, et al. The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson’s disease. Nat Commun. 2023;14(1):3651. · DOI · Paper page
  171. Pediaditakis I, Kodella KR, Manatakis DV, Hinojosa CD, Manolakos ES, Rubin LL, et al. Modeling Alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption in Parkinson’s disease. BioRxiv. 2021;2020–7. · doi:10.1101/2020.07.22.207340

Cited by

See all 56

Metadata

Authors
Balestri, W., Sharma, R., da Silva, V. A., Bobotis, B. C., Curle, A. J., Kothakota, V., Kalantarnia, F., Hangad, M. V., Hoorfar, M., Jones, J. L., Tremblay, M.-È., El-Jawhari, J. J., Willerth, S. M., & Reinwald, Y.
Venue
Journal of Neuroinflammation
Published
2024-01-23
Volume
21
Issue
1
ISSN
1742-2094
Cited by
56
References
59
Language
en
Licence
Funders
Medical Research Council (MR/X503125/1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.